Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 381

Sort by

Sort Order Select

Journal Articles

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Konstantinos Tzelepis, Etienne De Braekeleer, PhD MSc, Eliza Yankova, PhD, Justyna Rak, PhD, Demetrios Aspris, MSc, Ana Filipa Domingues, PhD, Richard Fosbeary, Alan Hendrick, PhD, Dan Leggate, PhD, Yaara Ofir-Rosenfeld, PhD, Alexandra Sapetschnig, PhD, Cristina Pina, MDDPhil, Mark Albertella, PhD, Wesley Blackaby, PhD, Oliver Rausch, PhD, George S. Vassiliou, FRCPath, MRCP, PhD, Tony Kouzarides, PhD

Blood (2019) 134 (Supplement_1): 403.

https://doi.org/10.1182/blood-2019-127962

Published: 2019

Journal Articles

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

Carolina D. Schinke, MD, Pingping Qu, Shmuel Yaccoby, PhD, Valeriy V Lyzogubov, MD PhD, Veronica MacLeod, Eileen M Boyle, Randal Shelton, Wen Ling, PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 508.

https://doi.org/10.1182/blood-2019-130595

Published: 2019

Journal Articles

A MYC Driven and Metabolite Executed Axis Controls the Subcellular Localization and Activity of TET DNA Hydroxylases and RNA Demethylases in B Cell Lymphomas

Zhijun Qiu, PhD, An-Ping Lin, MD, Shoulei Jiang, PhD, Binu Sasi, PhD, Patricia Dahia, MD PhD, Siyuan Zheng, PhD, Ricardo Aguiar, MD PhD

Blood (2019) 134 (Supplement_1): 114.

https://doi.org/10.1182/blood-2019-123101

Published: 2019

Journal Articles

SETDB1 Mediated H3K9 Methylation Suppresses MLL-Fusion Target Expression and Leukemic Transformation

Andrew G. Muntean, PhD, James Ropa, Nirmalya SAHA, PhD MSc, BSc, Hsiang-Yu Hu, BS, Justin Serio, Lili Zhao, Venkatesha Basrur, Alexei Nesvizhskii, Ivan Maillard, MD PhD

Blood (2019) 134 (Supplement_1): 110.

https://doi.org/10.1182/blood-2019-122610

Published: 2019

Journal Articles

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Malgorzata Gozdecka, PhD, Monika Dudek, MSc, Konstantinos Tzelepis, Aristi Damaskou, MSc, Vijay Baskar, PhD, Penny Wright, Graham Duddy, Eshwar Meduri, PhD, Milena Mazan, PhD, Kosuke Yusa, PhD, Brian J. P. Huntly, PhD MRCP, MB, FRCPath, George S. Vassiliou, FRCPath, MRCP, PhD

Blood (2019) 134 (Supplement_1): 111.

https://doi.org/10.1182/blood-2019-126505

Published: 2019

Journal Articles

Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Anthi Bouhla, MD, Frieda Kontsioti, PhD, Zoi Tsakiraki, MD, Sotirios Papageorgiou, MD PhD, Efthimia Mpazani, MD, Irene Glezou, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Athanasios Galanopoulos, MD PhD, Argiris Symeonidis, MD PhD, Nora-Athina Viniou, MD PhD, Kalliopi Zafeiropoulou, Ioannis Kotsianidis, MD PhD, Periklis Foukas, MD PhD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5403.

https://doi.org/10.1182/blood-2019-122424

Published: 2019

Journal Articles

Family Trio-Based Whole Genome Optical Mapping Identifies Candidate Structural Variations Predisposing Children to Acute Lymphoblastic Leukemia

Ute Fischer, PhD, Layal Yasin, PhD, Julia Täubner, PhD, Triantafyllia Brozou, MD, Arndt Borkhardt, MD

Blood (2019) 134 (Supplement_1): 5201.

https://doi.org/10.1182/blood-2019-130014

Published: 2019

Journal Articles

Protein Arginine Methyltransferase 1 Is Required for Maintenance of Normal Adult Hematopoiesis

Lei Zhu, MD, Xin He, PhD, Haojie Dong, PhD, Jie Sun, PhD, Hanying Wang, PhD, Yinghui Zhu, PhD, Feiteng Huang, Jingying Zou, Xiaoying Zhao, MD, Ling Li, PhD

Blood (2019) 134 (Supplement_1): 3708.

https://doi.org/10.1182/blood-2019-126050

Published: 2019

Journal Articles

Tumor Suppressor Function of Dnmt3b in Hematologic Malignancies Critically Depends on Its Catalytic Activity

Katarina Lopusna, PhD, Pawel Nowialis, PhD, Staci L. Haney, PhD, Ajay Abraham, PhD, Jana Opavska, Rene Opavsky, PhD

Blood (2019) 134 (Supplement_1): 3788.

https://doi.org/10.1182/blood-2019-130857

Published: 2019

Journal Articles

DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N 6 -Methyladenine

Xiaochang Liu, PhD, Jiuxia Pang, Christopher Seiler, Ryan Kempen, Hao Liu, Aref Al-Kali, MD, Y. Natalia Tretyakova, Mark Litzow, MD, Shujun Liu

Blood (2019) 134 (Supplement_1): 2513.

https://doi.org/10.1182/blood-2019-130490

Published: 2019

Journal Articles

Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML

Sagarajit Mohanty, MSc, Nidhi Jyotsana, PhD, Amit Sharma, PhD, Basem Othman, Arnold Kloos, PhD, Madhvi Mandhania, MSc, Renate Schottmann, Euan Ramsay, PhD, Hans- Peter Vornlocher, PhD, Arnold Ganser, MD, Felicitas Thol, MD, Michael Heuser, MD

Blood (2019) 134 (Supplement_1): 2545.

https://doi.org/10.1182/blood-2019-123709

Published: 2019

Journal Articles

CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34 + Cells

Emily A Saunderson, PhDBSc, Kevin Rouault-Pierre, PhDBSc, John G. Gribben, MD DSc, Gabriella Ficz, PhDBSc

Blood (2019) 134 (Supplement_1): 2517.

https://doi.org/10.1182/blood-2019-130267

Published: 2019

Journal Articles

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

Wendy Béguelin, PhD, Matthew R Teater, PhD, Cem Meydan, PhD, Jude M Phillip, PhD, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2768.

https://doi.org/10.1182/blood-2019-132263

Published: 2019

Journal Articles

BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML

Joseph M Brandwein, MD, Asmaa Basonbul, MSc

Blood (2019) 134 (Supplement_1): 2646.

https://doi.org/10.1182/blood-2019-129529

Published: 2019

Journal Articles

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

JI Hyun Chung, PhD, Shelby Sloan, BS, Peggy Scherle, PhD, Kris Vaddi, PhD, Said Sif, PhD, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 2777.

https://doi.org/10.1182/blood-2019-131020

Published: 2019

Journal Articles

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Kamal Menghrajani, MD, Sheng F Cai, MD PhD, Sean M. Devlin, PhD, Scott A. Armstrong, MD PhD, Richard Piekarz, MD PhD MS, BA, Michelle Rudek, PharmD, PhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 2655.

https://doi.org/10.1182/blood-2019-121926

Published: 2019

Journal Articles

N6-Methyladenosine RNA Methylation Regulators Contribute to Malignant Progression and Survival Prediction in Chronic Lymphocytic Leukemia

Ya Zhang, MD, Xiaosheng Fang, PhD, Na Chen, MD, Xiao Lv, PhD, Xueling Ge, PhD, Kang Lu, MD PhD, Xiangxiang Zhou, MD, Juan Yang, MM, Yang Han, MM, Shunfeng Hu, Xin Wang, MD PhD

Blood (2019) 134 (Supplement_1): 1738.

https://doi.org/10.1182/blood-2019-126469

Published: 2019

Journal Articles

The Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding and Represents a Druggable Target

Christophe Desterke, PhD, Sarah Pagliaro, Pharm D, Patricia Hugues, Annelise Bennaceur-Griscelli, MD PhD, Ali G Turhan, MD PhD

Blood (2019) 134 (Supplement_1): 1632.

https://doi.org/10.1182/blood-2019-124796

Published: 2019

Journal Articles

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Blood (2019) 134 (Supplement_1): 877.

https://doi.org/10.1182/blood-2019-131255

Published: 2019

Journal Articles

Interrogating RNA Binding Proteins as Novel Regulators of Fetal Hemoglobin Expression

Aoi Wakabayashi, BS, Jeremy D. Grevet, PhD, Xianjiang Lan, PhD, Malini Sharma, BS, Junwei Shi, PhD, Gerd A. Blobel, MD PhD

Blood (2019) 134 (Supplement_1): 966.

https://doi.org/10.1182/blood-2019-125901

Published: 2019

NARROW

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

A MYC Driven and Metabolite Executed Axis Controls the Subcellular Localization and Activity of TET DNA Hydroxylases and RNA Demethylases in B Cell Lymphomas

SETDB1 Mediated H3K9 Methylation Suppresses MLL-Fusion Target Expression and Leukemic Transformation

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group

Family Trio-Based Whole Genome Optical Mapping Identifies Candidate Structural Variations Predisposing Children to Acute Lymphoblastic Leukemia

Protein Arginine Methyltransferase 1 Is Required for Maintenance of Normal Adult Hematopoiesis

Tumor Suppressor Function of Dnmt3b in Hematologic Malignancies Critically Depends on Its Catalytic Activity

DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N 6 -Methyladenine

Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML

CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34 + Cells

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

N6-Methyladenosine RNA Methylation Regulators Contribute to Malignant Progression and Survival Prediction in Chronic Lymphocytic Leukemia

The Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding and Represents a Druggable Target

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Interrogating RNA Binding Proteins as Novel Regulators of Fetal Hemoglobin Expression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only